Treatment of chronic hepatitis B in clinical practice with entecavir or tenofovir

Table 3 Baseline characteristics of patients included in tenofovir studies n (%)[21]

Characteristic1	Study 103	Study 102	King’s College Cohort	United States cohort	European cohort	German cohort
Reference	[14]	14	[24]	[38]	[42]	[43]
n	176	250	60	28	302	184
Age, yr (mean ± SD or range)	34 ± 112	44 ± 112	403	36 ± 92	55 (19-80)	44 ± 142
Male	119 (68)	193 (77)	30 (50)	16 (58)	222 (74)	127 (69)
Race			NR		NR
White	92 (52)	161 (64)		1 (4)		140 (76)
Asian	64 (36)	63 (25)		27 (96)
Other	20 (11)	26 (10)
Region	Europe 55%, North America 27%, Australia and Asia 18%	Europe 63%, North America 21%, Australia and Asia 16%4	Europe	North America	Europe	Europe
Genotype			NR		NR	NR
A	94 (27)	33 (10)
B	68 (19)	46 (14)		18 (65)
C	111 (31)	57 (18)		10 (35)
D	55/173 (32)	156/243 (64)
HBeAg negative	0 (0)	250 (100)	46 (77)	0 (0)	241 (80)	127 (69)
HBV DNA, log10 IU/mL1	8.64 (1.076)25	6.86 (1.31)25	4.2 (0.3)6	7.74 (3.34-8.66)3	5.9 (1.4 -> 9)3	6.9
ALT, IU/L1	142 (102.81)2	127.5 (101.21)2	NR	52.5 (8-468)3	88 (11-3733)3
Cirrhosis	34/172 (20)	47/250 (19)	14 (23)	NR	105 (35)	20 (11)

¹Unless otherwise specified;

²mean ± SD;

³median (range);

⁴Australia or New Zealand;

⁵log10 copies/Ml;

⁶mean ± SE. ALT: Alanine transaminase; NR: Not reported; HBeAg: Hepatitis B e antigen.